Clinical trial · Observational
Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer
NCT07100288CI-TRIAL-00093016INFPELVrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Involvement of the infundibulopelvic ligament in ovarian cancer may be associated with decreased survival and related to paraaortic lymph node metastasis
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Adenocarcinoma | Ovarian Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Ovarian Cancer (OvCa) | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| resection of infundibulopelvic ligament | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- ovarian cancer patients
- interventionNames
- Other: resection of infundibulopelvic ligament
Primary outcomes (1)
- measure
- metastasis in infundibulopelvic ligament
- timeFrame
- Through study completion, an average of 5 year
- description
- To analyze the percentage of infundibulopelvic ligament involvement by cancer in patients with FIGO stage IA-IVB ovarian cancer.
Secondary outcomes (1)
- measure
- Presence of paraaortic lymph node metastasis
- timeFrame
- Through study completion, an average of 5 year
- description
- Evaluation of histologically positive para-aortic lymph nodes in patients with metastasis in the infundibulopelvic ligament
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ◦ Patients with epithelial ovarian cancer, including high- and low-grade serous, high- and low-grade endometrioid, mucinous (expansile and infiltrative types), and carcinosarcoma. * FIGO 2014 stage IA-IVB. * Patients undergoing primary surgery or interval surgery after 3-4 or 6 cycles of chemtherapy * Patients with no residual disease after surgery. * Patients with ECOG performance status 0-1. Exclusion Criteria: * ◦ Patients without epithelial ovarian cancer. * Patients with ECOG 2-4. * Patients who do not consent to participate in the study. * Patients who did not undergo complete staging surgery (including hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and omentectomy) or with residual disease after cytoreductive surgery.
References
Publications (3)
- RESULTTozzi R, Kohler C, Ferrara A, Schneider A. Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol. 2004 Apr;93(1):199-203. doi: 10.1016/j.ygyno.2004.01.004. PMID 15047236
- RESULTKleppe M, Kraima AC, Kruitwagen RF, Van Gorp T, Smit NN, van Munsteren JC, DeRuiter MC. Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. Int J Gynecol Cancer. 2015 Oct;25(8):1405-14. doi: 10.1097/IGC.0000000000000514. PMID 26397066
- RESULTFennimore IA, Simon NL, Bills G, Dryfhout VL, Schniederjan AM. Extension of ovarian tissue into the infundibulopelvic ligament beyond visual margins. Gynecol Oncol. 2009 Jul;114(1):61-3. doi: 10.1016/j.ygyno.2009.03.006. Epub 2009 Apr 9. PMID 19361838